(secondQuint)TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

 The drug being tested is TAK-659.

 This study will look at the OR in participants with relapsed or refractory DLBCL who take TAK-659.

 The study will enroll approximately 122 participants.

 Participants will be assigned to: cent TAK-659 60 mg to 100 mg All participants will be asked to take the tablets of TAK-659 at the same time each day throughout the study in 28-day cycle.

 This multi-center trial will be conducted in United States, United Kingdom, Spain, Italy, France, Canada, Germany.

 The overall time to participate in this study is approximately 48 months.

 Participants will be assessed for disease response and progression during the PFS follow-up of every 3 months after end of treatment (for participants who discontinue due to reasons other than disease progression) and OS follow-up of every 3 months from the last dose of study drug until death or conclusion of the study, whichever occurs first.

.

 TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)@highlight

The purpose of this study is to assess the efficacy of TAK-659 measured by independent radiologic review committee (IRC)-assessed overall response rate (ORR) in participants with relapsed or refractory DLBCL.

